Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to large-scale production and commercialization, aiming to become a globally positioned innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and an additional supplemental NDA under review, showcasing the company's strong market presence [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate critical registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals, including COVID-19 drugs, monkeypox concepts, viral prevention, and precision medicine [9].

Group 1 - The monkeypox sector experienced a decline, with companies such as Da An Gene hitting the daily limit down, while Capstone Bio, Bohui Innovation, Hefei China, Kehua Bio, Zhijiang Bio, and Wanfeng Bio also saw declines [1]

Group 1 - The monkeypox concept sector increased by 3.13%, ranking 8th among concept sectors, with 50 stocks rising, including Cap Bio, Mike Bio, and Zhijiang Bio, which hit the 20% limit up [1] - Notable gainers in the monkeypox sector included Wanfu Bio, Zhifei Bio, and Baipu Sais, which rose by 16.23%, 14.87%, and 12.58% respectively [1] - The sector saw a net inflow of 1.526 billion yuan from main funds, with 46 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] Group 2 - The top net inflow stock was Zhifei Bio, with a net inflow of 261 million yuan, followed by Zhongsheng Pharmaceutical, Junshi Bio, and Daan Gene with net inflows of 223 million yuan, 169 million yuan, and 165 million yuan respectively [2] - Daan Gene, Cap Bio, and Kewah Bio had the highest net inflow ratios at 46.21%, 29.57%, and 26.98% respectively [3] - The monkeypox concept sector's performance was supported by significant trading volumes, with stocks like Zhifei Bio and Daan Gene showing high turnover rates of 8.77% and 3.62% respectively [3][4]

Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and a mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [1][2]. Group 1: Stock Performance - On January 20, the stock price of New Industry fell by 2.05% to 56.76 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 0.29%, resulting in a total market capitalization of 44.597 billion CNY [1]. - Year-to-date, the stock price has increased by 0.91%, but it has decreased by 4.96% over the last five trading days, 3.80% over the last 20 days, and 8.32% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.428 billion CNY, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders was 1.205 billion CNY, reflecting a year-on-year decrease of 12.92% [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per shareholder, which is an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3].

Core Viewpoint - Junshi Biosciences has experienced fluctuations in stock price and trading volume, with a recent decline in share price despite a year-to-date increase. The company is involved in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with a significant portion of its revenue coming from drug sales [1][2]. Group 1: Stock Performance - On January 16, Junshi Biosciences' stock fell by 2.00%, trading at 36.72 CNY per share, with a total market capitalization of 37.7 billion CNY [1]. - The stock has increased by 7.49% year-to-date but has seen a decline of 6.33% over the last five trading days [1]. - The trading volume was 1.76 billion CNY, with a turnover rate of 0.62% [1]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06% [2]. - The company recorded a net profit attributable to shareholders of -596 million CNY, which is a 35.72% increase compared to the previous period [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased to 35,900, a rise of 15.17% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 12.96% to 21,361 shares [2]. Group 4: Company Overview - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, is based in Shanghai and focuses on the development and commercialization of monoclonal antibody drugs and other therapeutic proteins [1]. - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [1].

Core Viewpoint - Shengxiang Bio's stock price has shown fluctuations, with a recent decline of 2.04% and a total market value of 11.663 billion yuan, while the company has experienced a year-to-date stock price increase of 6.45% [1] Financial Performance - For the period from January to September 2025, Shengxiang Bio achieved operating revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49%, while the net profit attributable to shareholders decreased by 2.10% to 191 million yuan [2] - Cumulatively, since its A-share listing, Shengxiang Bio has distributed a total of 2.363 billion yuan in dividends, with 967 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Shengxiang Bio increased by 4.17% to 21,600, with an average of 26,772 circulating shares per person, which is a decrease of 4.01% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, a decrease of 1.7872 million shares compared to the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3] Business Overview - Shengxiang Bio, established on April 23, 2008, and listed on August 28, 2020, focuses on innovative gene technology, encompassing the research, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [1] - The company's main revenue sources include diagnostic reagents (87.39%), diagnostic instruments (5.71%), testing services (4.55%), and other supplementary services (2.34%) [1]

Core Viewpoint - Junshi Biosciences' stock price has shown fluctuations, with a recent decline of 2.06% and a year-to-date increase of 10.16%, indicating volatility in market performance [1][2]. Group 1: Stock Performance - As of January 15, Junshi Biosciences' stock price is reported at 37.63 CNY per share, with a total market capitalization of 38.634 billion CNY [1]. - The stock has experienced a 0.08% decline over the last five trading days, a 5.17% increase over the last 20 days, and a 3.49% decline over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences achieved a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06% [2]. - The company reported a net profit attributable to shareholders of -596 million CNY, which is a year-on-year increase of 35.72% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]. - The top ten circulating shareholders include notable ETFs, with E Fund's SSE STAR 50 ETF holding 19.3929 million shares, a decrease of 2.8203 million shares from the previous period [3].

Core Viewpoint - The stock of Capbio has experienced fluctuations, with a recent decline of 2.11% and a total market value of 3.898 billion yuan, while the company has shown a year-to-date increase of 12.08% in stock price [1] Group 1: Financial Performance - For the period from January to September 2025, Capbio reported a revenue of 486 million yuan, reflecting a year-on-year decrease of 20.38%, while the net profit attributable to shareholders was -128 million yuan, indicating a year-on-year increase of 51.25% [2] - Since its A-share listing, Capbio has distributed a total of 485 million yuan in dividends, with 193 million yuan distributed over the past three years [3] Group 2: Shareholder and Market Activity - As of December 31, the number of shareholders for Capbio was 26,900, a decrease of 1.70% from the previous period, with an average of 23,573 circulating shares per shareholder, which is an increase of 1.73% [2] - The main capital flow indicates a net outflow of 8.2821 million yuan, with significant selling activity from large orders [1]

Core Viewpoint - Junshi Biosciences' stock price has shown fluctuations, with a recent decline of 2.11%, while the company has experienced a year-to-date increase of 12.76% in stock value [1][2]. Group 1: Stock Performance - As of January 14, Junshi Biosciences' stock price is reported at 38.52 CNY per share, with a trading volume of 4.05 billion CNY and a market capitalization of 39.548 billion CNY [1]. - The stock has increased by 12.76% year-to-date, with a 1.90% rise over the last five trading days and a 5.30% increase over the last 20 days, while it has slightly decreased by 0.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences achieved a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was -596 million CNY, reflecting a year-on-year increase of 35.72% in losses [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences is 35,900, which is an increase of 15.17% compared to the previous period. The average number of circulating shares per shareholder is 21,361, a decrease of 12.96% [2]. - Among the top ten circulating shareholders, E Fund's SSE STAR 50 ETF holds 19.3929 million shares, a decrease of 2.8203 million shares from the previous period, while Huaxia's SSE STAR 50 ETF holds 18.9720 million shares, down by 1.0745 million shares [3].

Core Viewpoint - The stock of Hotgen Biotech has shown a mixed performance in recent trading, with a year-to-date increase of 18.12% but a slight decline over the past five days, indicating potential volatility in investor sentiment [1]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million yuan, representing a year-on-year decrease of 19.80% [2]. - The company experienced a net loss attributable to shareholders of 109 million yuan, which is a significant decline of 168.12% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average number of circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The stock price reached 191.36 yuan per share with a market capitalization of 17.741 billion yuan, and the trading volume was 168 million yuan, indicating active market participation [1]. Dividends and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.344 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase by ICBC Frontier Medical Stock A [3].